Skip to main
ICLR
ICLR logo

ICON (ICLR) Stock Forecast & Price Target

ICON (ICLR) Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 21%
Buy 36%
Hold 43%
Sell 0%
Strong Sell 0%

Bulls say

Icon has demonstrated a robust growth trajectory, with gross business awards increasing by 11% on a sequential basis, fueled by significant partnerships with both biotech and large pharmaceutical clients. The company has also successfully met or exceeded financial targets related to its PRA acquisition, positioning itself well amid funding environment uncertainties and a favorable client mix. Additionally, Icon's improved win rate in the clinical trial sector indicates a strong ability to capitalize on the expanding market for contract research organizations.

Bears say

Icon's stock outlook is negatively influenced by a revision in EBITDA margin expectations, which have fallen to the high-19% range from previous projections of around 20% for both the current year and 2025. The company faces significant downside risks, including potential slowdowns in clinical trial activity due to pharmaceutical reprioritizations, uncertainties in biotech funding, and challenges in achieving revenue synergies from its PRA transaction. Additionally, broader economic factors such as inflation and a slowdown in pharmaceutical R&D spending further exacerbate the challenges Icon may encounter moving forward.

ICON (ICLR) has been analyzed by 14 analysts, with a consensus rating of Buy. 21% of analysts recommend a Strong Buy, 36% recommend Buy, 43% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ICON and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ICON (ICLR) Forecast

Analysts have given ICON (ICLR) a Buy based on their latest research and market trends.

According to 14 analysts, ICON (ICLR) has a Buy consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $211.36, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $211.36, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ICON (ICLR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.